<DOC>
	<DOCNO>NCT02507856</DOCNO>
	<brief_summary>The multi-center , prospective PRODAST study investigate patient non-valvular atrial fibrillation ( AF ) experience ischemic stroke transient ischemic attack ( TIA ) recently ( ≤ 1 week ) without previous oral anticoagulation . It consist baseline visit 3 month central follow-up patient discharge dabigatran , vitamin K-antagonists , antiplatelets , oral antithrombotic treatment . Thus , data use dabigatran vitamin K-antagonists routine clinical practice collect describe dabigatran prescribe used population AF patient recent cerebrovascular event factor influence important outcome safety event . The utilization dabigatran assess regard treatment persistence , compliance , proportion patient discontinue treatment reason discontinuation well clinical endpoint major bleeding , stroke systemic embolism . Due fact patient treat accord local medical practice possible medication change observation period . In follow-up , data first well second prescribed medication use study . To explore long-term effect anticoagulation , survival one year assess .</brief_summary>
	<brief_title>Prospective Record Of Use Dabigatran Patients With Acute Stroke TIA</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Age ≥18 year enrollment Male female patient willing able provide write informed consent data transmission . For patient legally competent sign inform consent data transmission exceptions/special case describe protocol . Patient ischemic stroke TIA within last 7 day . Patient diagnose nonvalvular AF . Documentation AF 12 lead ECG , ECG rhythm strip , monitor printout , pacemaker/ICD electrocardiogram , Holter ECG ( duration AF episode least 30 second ) write physician´s diagnosis prior index event need enrolled patient . Presence mechanical heart valve , valve disease expect require valve replacement intervention ( surgical nonsurgical ) next 3 month . Current participation randomize clinical trial experimental drug device . Women childbearing age without anamnestic exclusion pregnancy use effective contraception nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>